Jonathan Kay to Risk Assessment
This is a "connection" page, showing publications Jonathan Kay has written about Risk Assessment.
Connection Strength
0.166
-
Kay J. Are There Benefits and Risks to Biosimilars from a Patient Perspective? Rheum Dis Clin North Am. 2019 08; 45(3):465-476.
Score: 0.100
-
Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40.
Score: 0.052
-
Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11.
Score: 0.014